Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Ta Yang

Showing results (251-260 of 310) with videos related to

Pageof 31
Sort By:
JTO Clinical and Research Reports|September 30, 2021
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced <i>ALK</i>-Rearranged NSCLC: An ASCEND-4 Subgroup AnalysisDaniel S W Tan, Sarayut Geater, Chong-Jen Yu, et al.
Biomedical Journal|July 4, 2016
Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesionsPing-Chih Hsu, Li-Chung Chiu, Shih-Hong Li, et al.
Thoracic Cancer|October 16, 2019
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression controlShih-Hao Huang, Allen Chung-Cheng Huang, Chin-Chou Wang, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 10, 2016
Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical interventionChia-Cheng Tseng, Chin-Chou Wang, Chang-Chun Hsiao, et al.
Frontiers in Oncology|October 19, 2023
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitorsPing-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, et al.
Therapeutic Advances in Medical Oncology|August 11, 2021
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancerAllen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, et al.
Cancers|January 21, 2022
Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor MutationChih-Hsi Scott Kuo, Tzu-Hsuan Chiu, Pi-Hung Tung, et al.
Scientific Reports|March 16, 2022
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasisTzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, et al.
Disease Markers|October 30, 2013
Levels of circulating microparticles in lung cancer patients and possible prognostic valueChia-Cheng Tseng, Chin-Chou Wang, Huang-Chih Chang, et al.
Targeted Oncology|February 22, 2023
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in TaiwanPing-Chih Hsu, Suey-Haur Lee, Li-Chung Chiu, et al.
Pageof 31

Showing results (251-260 of 310) with videos related to

Sort By:
Pageof 31
JTO Clinical and Research Reports|September 30, 2021
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced <i>ALK</i>-Rearranged NSCLC: An ASCEND-4 Subgroup AnalysisDaniel S W Tan, Sarayut Geater, Chong-Jen Yu, et al.
Biomedical Journal|July 4, 2016
Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesionsPing-Chih Hsu, Li-Chung Chiu, Shih-Hong Li, et al.
Thoracic Cancer|October 16, 2019
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression controlShih-Hao Huang, Allen Chung-Cheng Huang, Chin-Chou Wang, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 10, 2016
Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical interventionChia-Cheng Tseng, Chin-Chou Wang, Chang-Chun Hsiao, et al.
Frontiers in Oncology|October 19, 2023
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitorsPing-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, et al.
Therapeutic Advances in Medical Oncology|August 11, 2021
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancerAllen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, et al.
Cancers|January 21, 2022
Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor MutationChih-Hsi Scott Kuo, Tzu-Hsuan Chiu, Pi-Hung Tung, et al.
Scientific Reports|March 16, 2022
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasisTzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, et al.
Disease Markers|October 30, 2013
Levels of circulating microparticles in lung cancer patients and possible prognostic valueChia-Cheng Tseng, Chin-Chou Wang, Huang-Chih Chang, et al.
Targeted Oncology|February 22, 2023
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in TaiwanPing-Chih Hsu, Suey-Haur Lee, Li-Chung Chiu, et al.
Pageof 31